ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "gout"

  • Abstract Number: 0668 • ACR Convergence 2021

    Patient Perspectives and Preferences Regarding Gout and Gout Management: Impact on Adherence

    Min Kyung Chung1, Sung Soo Kim2, Yun-Hong Cheon3, Seung Jae Hong4, Hyo Jin Choi5, Mi Ryoung Seo5, Ji Won Hwang6, Joong Kyong Ahn7, Sang-Heon Lee8, Hong Ki Min8, Hoon-Suk Cha9, Shin-Seok Lee10, Jennifer Lee11, Ki Won Moon12, Chang-Keun Lee13, Hyun-Ok Kim14, Young Sun Seo15, Seung-Cheol Shim16, Seong Wook Kang16, Jinhyun Kim16, Sang Tae Choi17, Jung Soo Song17 and Jisoo Lee1, 1Ewha Womans University College of Medicine, Seoul, Republic of Korea, 2Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea, 3Gyeongsang National University Hospital, Jinju, Republic of Korea, 4Kyung Hee University Hospital, School of Medicine, Kyung Hee University, Seoul, Republic of Korea, 5Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, 6Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea, 7Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 8Konkuk University Medical Center, Seoul, Republic of Korea, 9Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 10Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, 11Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea, 12Kangwon National University School of Medicine, Chuncheon, Republic of Korea, 13Asan Medical Center, SEOUL, Republic of Korea, 14Gyeongsang National University College of Medicine, Changwon, Republic of Korea, 15Gyeongsang National University Hospital, Changwon, Republic of Korea, 16Chungnam National University, Chungnam National University Hospital, Daejeon, Republic of Korea, 17Chung-Ang University School of Medicine, Seoul, Republic of Korea

    Background/Purpose: Patient-centered management is becoming increasingly important in gout, but there are limited studies exploring patients’ perspectives and preferences. We aimed to investigate patients’ perspectives…
  • Abstract Number: 1095 • ACR Convergence 2021

    Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression

    Ahsan Iqbal1, Sumir Brahmbhatt1, Maheswari Muruganandam2, David Cisneros3, Adnan Kiani2, Fatemeh Farshami4, Jaren Trost5, N. Suzanne Emil2, Sharon Nunez1 and Wilmer Sibbitt2, 1UNM, Albuquerque, NM, 2University of New Mexico, Albuquerque, NM, 3University of New Mexico School of Medicine, Albuquerque, NM, 4University of New Mexico, Albuquerque, MD, 5Optum, Albuquerque, NM

    Background/Purpose: Arthrocentesis is critical for diagnosis and therapy of joint disease; however, it is very difficult to obtain diagnostic fluid from an arthritic but clinically…
  • Abstract Number: 1580 • ACR Convergence 2021

    Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis

    Richard Reynolds1, Riku Takei1, Jeffrey Edberg1, Nicholas Sumpter1, Tony Merriman2 and Megan Leask1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Dunedin, New Zealand

    Background/Purpose: Gene expression studies of whole blood represent a powerful approach for understanding the pathogenesis of gout because differentially expressed transcripts may reflect the activation…
  • Abstract Number: 0669 • ACR Convergence 2021

    Early-Onset Gout (EOG) Patients Are an Important and Recalcitrant Phenotype Warranting Further Investigation: A Systematic Review

    Anthony Amatucci1, Brian LaMoreaux2 and David Bulbin3, 1Horizon Therapeutics, West Orange, NJ, 2Horizon Therapeutics plc, Deerfield, IL, 3Geisinger Health System, Danville, PA

    Background/Purpose: Data suggests that the number of patients with early-onset gout (EOG), defined as patients under the age of 40 years, is increasing1. There is…
  • Abstract Number: 1099 • ACR Convergence 2021

    Characteristics and Outcomes of Myocardial Infarction in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Gout and Osteoarthritis Patients Using the National Inpatient Sample Database from 2002-2018

    Sonia Gupta1, Vinay thallapally2, Sarah Aurit2, Rouhin sen3 and Joseph Nahas2, 1Creighton University School of Medicine, Omaha, NE, 2Creighton University, Omaha, NE, 3Colorado University Anschutz Medical Campus, Denver, CO

    Background/Purpose: Patients with the autoimmune rheumatic disease have an increased risk of acute myocardial infarction (MI). Our study was designed to compare the prevalence, characteristics…
  • Abstract Number: 1581 • ACR Convergence 2021

    Genetic Effects on the Transition from Hyperuricemia to Gout

    Nicholas Sumpter1, Riku Takei1, Richard Reynolds1 and Tony Merriman2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Dunedin, New Zealand

    Background/Purpose: There is clear evidence of genetic control of hyperuricemia resulting in increased gout risk, however genetic control of the transition from hyperuricemia to gout…
  • Abstract Number: 0671 • ACR Convergence 2021

    Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices

    Aaron Broadwell1, John Albert2, Brian LaMoreaux3 and Lissa Padnick-Silver3, 1Rheumatology and Osteoporosis Specialists, Shreveport, LA, 2Rheumatic Disease Center, Milwaukee, WI, 3Horizon Therapeutics plc, Deerfield, IL

    Background/Purpose: Patients with uncontrolled or refractory gout have heavy disease burden,1 but few treatment options. Pegloticase is effective for lowering serum urate (SU) in these…
  • Abstract Number: 1184 • ACR Convergence 2021

    Voluntary Online Gout Module: Housestaff Utilization and Efficacy

    Sarah Tarplin1, Susan Kroop2 and Catherine Deffendall2, 1Vanderbilt Universty Medical Center, nashville, TN, 2Vanderbilt University, Nashville, TN

    Background/Purpose: All Internal Medicine (IM) physicians should be competent in gout diagnosis and management. The purpose of this study is to assess learner engagement with…
  • Abstract Number: 1895 • ACR Convergence 2021

    Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry

    Nevin Hammam, Jing Li, Julia L Kay, Jinoos Yazdany and Gabriela Schmajuk, University of California San Francisco, San Francisco, CA

    Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…
  • Abstract Number: 0672 • ACR Convergence 2021

    Does Obesity Affect Gout Risk Differently Among Genetically Predisposed Individuals?: Sex-Specific Prospective Cohort Study Findings over >32 Years

    Chio Yokose1, Natalie McCormick2, Na Lu3, Amit Joshi2 and Hyon K. Choi4, 1Massachusetts General Hospital, Waltham, MA, 2Massachusetts General Hospital, Boston, MA, 3Arthritis Research Canada, Vancouver, BC, Canada, 4Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Two recent analyses of the Global Burden of Disease Study reported on the rising global burden of gout (Safiri A&R 2020, Xia Rheumatology 2020).…
  • Abstract Number: 1449 • ACR Convergence 2021

    Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?

    Sarah Stewart1, Amanda Phipps-Green2, Gregory Gamble1, Lisa Stamp3, William Taylor4, Tuhina Neogi5, Tony Merriman6 and Nicola Dalbeth1, 1University of Auckland, Auckland, New Zealand, 2University of Otago Dunedin, Dunedin, New Zealand, 3University of Otago, Christchurch, Christchurch, New Zealand, 4University of Otago Wellington, Auckland, New Zealand, 5Boston University School of Medicine, Boston, MA, 6University of Alabama at Birmingham, Dunedin, New Zealand

    Background/Purpose: Elevated serum urate is the most important risk factor for developing gout. However, in longitudinal cohort studies, a small proportion of people with normal…
  • Abstract Number: 1897 • ACR Convergence 2021

    A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout

    Nicola Dalbeth1, Anthony Doyle1, Karen Billington1, Gregory Gamble1, Paul Tan1, Kieran Latto1, Trish Parshu Ram1, Ravi Narang1, Rachel Murdoch1, David Bursill1, Borislav Mihov1, Lisa Stamp2 and Anne Horne1, 1University of Auckland, Auckland, New Zealand, 2University of Otago, Christchurch, Christchurch, New Zealand

    Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
  • Abstract Number: 0673 • ACR Convergence 2021

    The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study

    Aniqa Faraz1, Sabeeh Islam2, Joseph Grisanti3 and Shumaila Iqbal4, 1University at Buffalo-CHS Sisters of Charity, Grand Island, NY, 2Brigham and Women's Hospital Cardiology, Boston, MA, 3Buffalo Rheumatology & Medicine, Orchard Park, NY, 4University of Cincinnati, Cincinnati, OH

    Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…
  • Abstract Number: 1529 • ACR Convergence 2021

    Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy

    Huifeng Yun1, Brian LaMoreaux2, Lang Chen3, Stephanie Ledbetter3, Megan Francis-Sedlak2, Kenneth Saag3, Ted Mikuls4 and Jeffrey Curtis5, 1University of Alabama Birmingham, Birmingham, AL, 2Horizon Therapeutics plc, Deerfield, IL, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Nebraska Medical Center, Omaha, NE, 5Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
  • Abstract Number: 1899 • ACR Convergence 2021

    Mortality in Patients with Sub-Optimally Treated Gout in the Veteran’s Health Administration: A National Retrospective Cohort Study

    Lindsay Helget1, Bryant England1, Punyasha Roul1, Harlan Sayles1, Alison Petro1, Tuhina Neogi2 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2Boston University School of Medicine, Boston, MA

    Background/Purpose: Patients with gout have an increased risk of mortality. Current ACR guidelines for the treatment of gout recommend a treat-to-target approach with titration of…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 45
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology